Damora Therapeutics, Inc.(DMRA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Damora Therapeutics, Inc. (DMRA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. DMRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of DMRA by reported 13-F value include FMR, Fairmount Funds Management, Avoro Capital Advisors, based on the most recent SEC filings. DMRA trades on the Nasdaq exchange and files with the SEC under CIK 1800315. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DMRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Damora Therapeutics, Inc. directly from SEC EDGAR.

Net Income

$-31.2M

Institutions holding DMRA

Institutional investors reporting a position in Damora Therapeutics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
FMR9,232,979$240.1M2026-06-30
Fairmount Funds Management8,713,000$226.6M2026-06-30
Avoro Capital Advisors3,783,000$98.4M2026-06-30
VR Adviser3,603,595$93.7M2026-06-30
BlackRock3,162,068$82.2M2026-06-30
FCPM III SERVICES B.V.2,441,000$63.5M2026-06-30
RA CAPITAL MANAGEMENT, L.P.2,399,702$62.4M2026-06-30
VIKING GLOBAL INVESTORS2,311,082$60.1M2026-06-30
Jupiter Topco2,282,804$59.3M2026-06-30
Remedium Capital Partners2,045,473$53.2M2026-06-30
DMRA

Damora Therapeutics, Inc.

DMRA
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-31.17M

EPS (Diluted)

Q2 2026
EDGAR

$-0.39

ROIC

Q2 2026
EDGAR

-27.1%

Top Institutional Holders

as of Q2 2026
$1.67B total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…